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Introduction
omplicated grief (CG) is a debilitating condi-
tion that is estimated to affect 6% to 25% of individuals
who experience the loss of a loved one.
1-3 Recent
research indicates that CG-specific psychological inter-
ventions are effective in reducing symptoms of CG.
4
However, data is still scarce on the potential efficacy of
medication strategies in the management of CG symp-
toms. Given that many of those suffering from CG do
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Complicated grief (CG) is a common and often under-acknowledged cause of profound impairment experienced
after the loss of a loved one. Although both clinical and basic research suggests that pharmacological agents might
be of use in the treatment of CG, research on pharmacological approaches to this condition is still scarce. Three
open-label trials and one randomized trial on bereavement-related depression suggest that tricyclic antidepressants
may be effective, although they may be more efficacious for depressive symptoms than for grief-specific symptoms.
Four open-label trials (total number of participants, 50) of selective serotonin reuptake inhibitors (SSRIs) have yielded
results, providing very preliminary support that they might be effective in the treatment of CG, both as a stand-
alone treatment and in conjunction with psychotherapeutic interventions. These more recent studies have shown
an effect on both depression and grief-specific scales. Furthermore, therapeutic interventions for CG may be more
effective in conjunction with SSRI administration. Given the small number of pharmacological studies to date, there
is a need for randomized trials to test the potential efficacy of pharmacological agents in the treatment of CG.     
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not access mental health services
5 and are thus more
likely to only be seen by primary care physicians, there
is a need to better understand which pharmacological
interventions are most likely to be efficacious, and for
research to provide an evidence base of randomized
controlled trials examining the efficacy of these agents.
In this brief review, the rationale for a pharmacological
approach to treating CG and current available data will
be highlighted. Finally, further avenues for research will
also be explored. 
Rationale for a pharmacological approach to
the treatment of complicated grief
Clinical rationale
CG is currently being considered for inclusion as a for-
mal disorder in the fifth edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5).
6-8
However, some authors have highlighted that CG shares
common features with two other DSM-IV disorders,
namely major depressive disorder (MDD) and post-trau-
matic stress disorder (PTSD).
6 Although most studies
report that only a subset of individuals with CG meet cri-
teria for MDD,
9-11 both CG and depression include symp-
toms such as crying, sadness (though not necessarily gen-
eralized), sleep disturbances, and suicidal ideation. 
Although the nature of the stressor is different in CG
(losing a loved one as opposed to confrontation with a
life-threatening situation in PTSD), individuals with CG
have similarly experienced a major life stressor.
Furthermore, both of these conditions share some symp-
toms in common such as intrusive memories, sleep dis-
turbances, avoidance, and feeling estranged from others.
PTSD and CG nonetheless have many differences as well;
for example, while PTSD has been conceptualized as a
fear-based disorder in response to traumatic experiences,
CG has been conceptualized as resulting from a major
attachment loss with associated difficulties processing the
loss and adjusting to life without the deceased.
6
Over the past decade, antidepressants, and especially
selective serotonin reuptake inhibitors (SSRIs), have
been widely demonstrated to be effective in reducing
both MDD symptoms
12 and PTSD symptoms,
13 includ-
ing, sadness, suicidal ideation, and intrusive thoughts. In
a meta-analysis examining the efficacy of pharma-
cotherapy in PTSD, Stein et al reported that SSRIs were
more effective than placebo in reducing PTSD symptom
severity (weighted mean difference on the clinician-
administered PTSD scale = -5.95, 95% confidence inter-
val = -8.9 to -3.0, pooled n =1907), and in inducing treat-
ment response (relative risk = 1.59, 95% confidence
interval =1.39 to 1.82, pooled n =999).
13 Given the clini-
cal overlap between CG and both MDD and PTSD, as
well as the demonstrated broad efficacy of SSRIs across
mood and anxiety disorders, it is hypothesized that
SSRIs might also be effective for CG, a debilitating con-
dition that shares symptoms with both MDD and PTSD
and may be conceptualized as a stressor-induced affec-
tive syndrome.
Neurobiological rationale
In an animal study, Fontenot et al reported that
macaques exposed to a chronic social stress reminiscent
of bereavement (ie, deprivation of social group mem-
bers) exhibited significantly lower serotonin and sero-
tonin metabolite levels in the prefrontal cortex com-
pared with their counterparts who were not stressed by
a similar deprivation.
14These findings suggest that social
stress following separation may result in a long-term
reduction of serotoninergic activity in the brain. Thus,
the loss of a close group member has been demonstrated
to result in neurotransmitter changes in a brain region
critical for executive and psychological functioning.
Given the genetic and neurobiological similarities
between macaques and humans, this might be consid-
ered as an animal model of CG.
15 In terms of neurobio-
logical mechanisms, it thus appears that both depression
and grief may share lower levels of serotonergic brain
activity. In addition, it has been demonstrated in humans
that subjects suffering from complicated grief (as
opposed to simple uncomplicated grief) show differ-
ences in diurnal cortisol profiles,
16 also suggesting that
complicated grief pathophysiology may involve some of
the same molecular pathways as have been character-
ized for MDD. 
In addition to the molecular changes described above,
patients with complicated grief may have a pre-existing
genetic vulnerability to suffering a more debilitating ill-
ness than those who experience uncomplicated grief. By
playing a major role in the degradation of amines, the
enzymatic activity of monoamine oxidase A (MAO-A)
affects serotonergic neurotransmission. Recent research
examining a genetic variation in the MAO-A gene also
suggests that in the context of major depression, a cer-
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with the occurrence of complicated grief in women.
15
Taken together, these neurobiological and genetic find-
ings provide early support that CG may be associated
with certain alterations in the serotonergic neurotrans-
mission systems, and that the pharmacological manipu-
lation of these systems might provide a potential avenue
for treating CG.
Early research: 
bereavement-related depression
While research on the pharmacological treatment of CG
has only recently emerged paralleling the progress in
defining this condition, earlier work investigating the
efficacy of antidepressants on bereavement-related
depressive symptoms has yielded interesting results. 
The first open-label antidepressant trial was conducted by
Jacobs et al in a sample of 10 widows and widowers.
17The
authors reported that after 4 weeks of treatment with
desipramine (75 mg to 150 mg/day), 4 of the participants
were rated as “very much improved” and 3 as “much
improved” on the Clinical Global Impression –
Improvement (CGI-I) scale, while only one participant
dropped out of the study due to side effects. Although this
study also yielded significant reductions in depressive
symptoms as measured by the Hamilton Depression
Rating Scale (HDRS
18) in these seven participants, only a
subset of these responders (three out of seven) also expe-
rienced a significant improvement in grief intensity.
17
A second open-label trial was also conducted in a sam-
ple of bereaved spouses. Pasternak et al investigated the
potential efficacy of another tricyclic antidepressant,
nortriptyline, on bereavement-related depressive symp-
toms, sleep and grief intensity.
19 The authors reported
that, among the 13 participants, depressive symptoms
measured by the HDRS and the Beck Depression
Inventory (BDI
20) and sleep quality assessed by the
Pittsburgh Sleep Quality Index were significantly
reduced after a median treatment period of 6.4 weeks.
Similarly to Jacobs et al’s study, results indicated some
improvement in grief intensity as measured by the Texas
Revised Inventory of Grief (TRIG
21), although the clin-
ical significance of this improvement was marginal
(overall improvement rate of 9.3%).
Zisook et al reported results of another open-label trial
of bereavement-related depression.
22 In this study, the
authors did not investigate a tricyclic, but a newer-gen-
eration antidepressant. Within 8 weeks of losing their
spouses, 
22 participants were treated with 150 mg to 300
mg/day of buproprion SR. Fourteen of the subjects com-
pleted the 8-week trial (dropout rate =36%). Although
no formal psychotherapy was provided, time was allo-
cated during the sessions for listening to patients’ con-
cerns. Both study completers and the intention-to-treat
sample showed statistically significant improvements in
depressive symptoms as measured by the HDRS and the
Clinical Global Impression-Severity (CGI-S). Regarding
measures of grief intensity, both the completers and the
intention-to-treat samples also showed statistically sig-
nificant improvements on the Inventory of Complicated
Grief (ICG
23). While improvement on the TRIG was also
significant in the intention-to-treat sample, there was
only a trend towards significance in the completers sam-
ple. Again, improvement in grief intensity, although sta-
tistically significant in this study, seems to be quite mod-
est relative to the improvement noted in depressive
symptoms. In the intention-to-treat sample, after 8 weeks
of treatment, CG symptoms decreased by 5% on the
TRIG and 18% on the ICG, while depressive symptoms
decreased by 54% on the HDRS.
Currently, results from only one randomized controlled
trial of the pharmacological treatment of bereavement
depression have been published.
24 Reynolds et al ran-
domized 80 older adults to 16 weeks of either nortripty-
line plus interpersonal therapy (n=16), placebo plus
interpersonal therapy (IPT, n=17), nortriptyline alone
(n=25), or placebo alone (n=22).
24 Participants were
required to meet criteria for MDD plus a certain level
of grief intensity as defined by a score on the TRIG of
at least 45. Sixty-nine percent of the participants in the
nortriptyline plus IPT achieved remission, defined by a
score of 7 or below for 3 consecutive weeks on the 17-
item HDRS, while 29%, 56%, and 45% achieved remis-
sion in the placebo plus IPT, nortriptyline alone and
placebo alone groups, respectively. Controlling for age
as a covariate, the authors found a significant effect of
the nortriptyline, but no significant effect of IPT nor any
additive effect for nortriptyline combined with IPT.
However, the authors failed to demonstrate any differ-
ential effect of any of these treatments on improvement
rates of grief intensity as measured by both the TRIG
and the ICG. The main results from these studies are
reported in Table I.
In summary, some evidence suggests that antidepres-
sants, in particular tricyclics, may be effective for reduc-
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depression, even if their effect might not be as dramatic
or specific for grief intensity. Although these findings
provide valuable information about the treatment of
grief symptoms in the context of bereavement-related
depression, it has been consistently shown that compli-
cated grief is a clinical entity distinct from depression.
1
It is thus complicated to isolate the efficacy of pharma-
cological treatments for grief symptoms in the context
of co-occurring depression. As individuals with CG often
present without meeting full criteria for depression,
additional studies are needed to elucidate the efficacy of
152
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Authors (year) Design Population Duration Time since loss Drug Results
Bereavement-related depression
Jacobs et al  Open-label (ITT) n=10, age range=26-65,  4 weeks Desipramine,  Depressive symptoms: 
(1987)
17 80% women 75-150 mg/day 70% responders 
Grief symptoms: 37.5% responders 
Pasternak et al Open-label (SC) n=13 CG patients, 61.5% median= mean=  Nortriptyline Depressive symptoms
(1991)
19 women, mean age=71.1 6.4 weeks 11.9 months mean dose=  improvement rate: 68%
49.2 mg/day Grief symptoms 
improvement rate: 9%
Zisook et al  Open-label (ITT) n=22 for ITT sample, 8 weeks 4-6 weeks Bupropion, ITT: Depressive symptoms
(2001)
22 77.3% women,  flexible 150- improvement rate: 54%
mean(SD) age=63.5  200 mg/day ITT: Grief symptoms improvement
(11.0) rate: ICG= 18%, TRIG= 5%
Open-label (SC) n=14 for SC sample 8 weeks 4-6 weeks Bupropion, SC: Depressive symptoms 
flexible 150- improvement rate: 73%
200 mg/day SC: Grief symptoms improvement 
rate: ICG=22%, TRIG-9%
Reynolds et al  RCT n=25 nortriptyline vs  16 weeks mean=8.1 Nortriptyline, Depressive symptoms:
(1999)
24 n=22 placebo (vs n=17 IPT  months mean dose= nortriptyline group=56% remission 
vs n=16 nortriptyline+IPT),  66 mg/day placebo group=45% remission vs
Major Depressive Disorder,  nortriptyline+IPT group=69% remission
TRIG≥45, 72.5% women,  Grief symptoms: no differential
mean age=66.1 effect of treatments
Complicated grief
Zygmont et al  Open-label (SC) n=15 mean age=57,  16-week median =17 Paroxetine, Depressive symptoms
(1998)
25 icg≥20, 73.3% women months flexible 20- improvement rate: 51%
50 mg/day Grief symptoms 
improvement rate: ICG=48%
Shear et al  Open-label n=17, ICG≥30 16 weeks mean=3.9 years Escitalopram, ITT: Grief symptoms
(2006)
28 (modified ITT) flexible 10-  improvement rate: ICG=24%
20 mg/day
Open-label (SC) n=7, ICG≥30 SC: Grief symptoms 
improvement rate: ICG=35%
Simon et al  Case series n=4, ICG≥25, 100% 10 weeks > 6 months Escitalopram, Complicated grief: 100% responders
(2007)
26 women, mean (SD)  flexible 10- Grief symptoms
age=41.75 (14.4)  20 mg/day improvement rate: ICG=76%
Hensley et al  Open-label (SC) n=14 with Major  12 weeks > 6 months Escitalopram, Grief symptoms
(2009)
27 Depressive Disorder and CG flexible 10- improvement rate: ICG=21%
20 mg/day
Table I. Summary of results of medication trials in bereavement-related depression and complicated grief. CG, complicated grief RCT, randomized
controlled trial; SC, study completers; ITT, intention to treat; TRIG, Texas revised inventory of grief; ICG, inventory of complicated grief
PAGES_13_AG_1001_BA.qxd:DCNS#52  6/06/12  12:06  Page 152pharmacological treatments for CG, both with and with-
out MDD comorbidity to better characterize the effects
on grief specific symptoms. 
Pharmacological approach to the treatment
of complicated grief
Pharmacological trials of complicated grief (also for-
merly known as “prolonged grief disorder” or “traumatic
grief”) are scarce, likely in part because attention to this
condition as a potential formal diagnostic entity has only
recently occurred, with different criteria sets proposed
that are still the focus of ongoing debate.
6 Further, the
lack of inclusion of CG in the DSM as a formalized diag-
nosis to date has implications for FDA trials and limits
pharmaceutical development targeting CG. Also, with-
out a formalized diagnosis, few patients are assessed for
CG, and clinicians do not have CG-specific billing codes,
together limiting targeted treatment and naturalistic
study of pharmacotherapy already administered to help
seeking patients in practice settings. This issue is of crit-
ical importance to debates about whether CG should be
included in DSM-5. 
Selective serotonin reuptake inhibitors
One publication has reported a post-hoc comparison of
paroxetine and nortriptyline for the treatment of trau-
matic grief (an earlier term in the literature for CG).
Zygmont et al examined open paroxetine (flexible dos-
ing, 10 mg to 50 mg/day) administered for 16 weeks to 21
individuals with traumatic grief simultaneously partici-
pating in a psychotherapy treatment development study.
25
Fifteen participants completed at least 6 weeks of med-
ication, and 13 the full course of the trial (16 weeks). In
this study, measures of grief intensity (using the ICG) and
measures of depression (using the HDRS rating scale)
both declined by 48% and 51% respectively in the parox-
etine-treated groups. This study also compared these
results with an ongoing study of bereavement related
depression in which patients were treated with nor-
triptyline (with and without psychotherapy; n=22 for at
least 6 weeks, n=18 for 16 weeks). Again, both of the anti-
depressant-treated groups showed significant reductions
in both grief and depressive symptoms (using the ICG
and HDRS rating scales), even though depressive symp-
toms responded earlier in the treatment course than the
improvement in grief symptoms. 
In another uncontrolled study, Simon et al treated and
prospectively assessed four women with a primary diag-
nosis of CG (defined as a score of 25 or above on the
ICG, at least 6 months after the death of a loved one),
treated with escitalopram.
26 At the end of the 10-week
trial, all participants were rated as “very much
improved” on the CGI-I. Both complicated grief symp-
toms assessed by the ICG and depressive symptoms as
assessed by the HDRS were significantly decreased. 
A more recent open-label study investigating the poten-
tial efficacy of escitalopram was conducted in 30 indi-
viduals with bereavement-related depression.
27 In this
trial, participants meeting criteria for MDD after the loss
of a loved one were treated for 12 weeks with a mean
final dose of 13.1 mg/day of escitalopram. Of the 29 indi-
viduals studied, 14 were diagnosed with complicated
grief in addition to MDD, whereas 15 of the subjects met
criteria for MDD but not for CG. When the results of
treatment were analyzed by CG diagnosis, mean ICG
scores improved by 21% in the CG group, and by 39%
in the uncomplicated grief group. Given the small sam-
ple size, however, this difference was not statistically sig-
nificant. Defining treatment response as “very much
improved” and or “much improved” on the CGI-I scale,
45% of the whole sample were responders in terms of
grief symptoms, and 83% in terms of depressive symp-
toms. 
Another open-label trial
28 was conducted in 17 partici-
pants with CG (scoring ≥30 on the ICG, more than 6
months after a loss) as a primary disorder. Participants
received escitalopram 10 mg/day, with an option to
increase the dose to 20 mg/day, at week 4. At 16 weeks,
the response rate was of 38% with a decrease in mean
ICG score of only 24% in the intention-to-treat sample
(those who attended at least one session). The main
results from these studies are reported in Table I.
Other medications
To the best of our knowledge, there is no report on the
primary efficacy of benzodiazepines for the treatment of
CG. However, an earlier randomized controlled trial has
investigated the use of diazepam vs placebo in the med-
ical management of recent grief.
29 In this study,
30 recently
bereaved individuals were randomized to receive a bot-
tle containing 20 tablets of either diazepam (2 mg) or
placebo for PRN use during the following 6 weeks. At the
7-month follow-up, analyses failed to show any significant
153
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differences between the two groups in terms of grief
symptom severity as measured by the Bereavement
Phenomenology Questionnaire (BPQ
30). Interestingly,
those receiving diazepam had more sleep problems than
those assigned to placebo. This is consistent with research
on PTSD suggesting that benzodiazepines might actually
increase the severity of PTSD.
31-33 Furthermore, recent
data suggests that the use of benzodiazepines in the after-
math of a loss might also lead to long-term prescription
dependence in elderly individuals.
34
Combining pharmacological and 
psychological interventions
In their 2001 publication, Zisook et al reported that dur-
ing their trial, several patients specifically stated that the
treatment of depressive symptoms allowed them “to
grieve more intensely” and “confront situations that they
had been avoiding when more depressed.”
22 This sug-
gests that a concurrently prescribed antidepressant
might improve outcomes with psychological grief spe-
cific interventions based on behavioral techniques. As
summarized above, an earlier study by Reynolds et al
24
failed to show a significant interaction effect of nor-
triptyline and interpersonal therapy for the treatment of
bereavement-related depression. However, in Shear et
al’s randomized controlled trial of complicated grief
therapy (CGT) vs interpersonal therapy for loss (IPT)
in complicated grief
35 in which stable medication was
allowed during the course of the study, concomitant anti-
depressant use was marginally associated with a better
outcome in each arm (for both CGT and IPT). In follow-
up analysis, Simon et al more closely examined medica-
tion effects based on data obtained from the same sam-
ple.
36 Although results for each group were only
marginally significant, they reported that in the full sam-
ple (n=95), even after controlling for covariates (age,
gender, race, and psychiatric comorbidity), participants
who were prescribed a stable dose of antidepressant dur-
ing the trial were more than two times more likely to be
treatment responders (“very much improved” and or
“much improved” on the CGI-I scale) than those who
were not (adjusted odds ratio=2.7, 95% confidence inter-
val (CI)=1.1 – 6.8). Furthermore, examination of
dropout rates revealed that use of antidepressants was
associated with a sixfold increased rate of study com-
pletion in the CGT arm (adjusted for psychiatric comor-
bidity odds ratio=6.3, 95%CI=1.2 – 34.2). However, anti-
depressant use was not associated with such an increase
in study completion rate in the group allocated to IPT.
Thus it appears that antidepressant treatment may allow
participants to engage more fully or complete participa-
tion in CG specific psychotherapy interventions as com-
pared with those treated with therapy alone, although
conclusions are limited by the naturalistic, open nature
of medication prescribing in this sample. The authors
also examined the effect of naturalistic prescription of
stable doses of benzodiazepines. Benzodiazepine use
was significantly associated with an increase in treatment
response rate in the IPT group, but not in the CGT
group, nor in the whole sample. The use of benzodi-
azepines was not significantly associated with dropout
rates in either group.
Summary and future directions
Although similar overlapping entities such as patholog-
ical grief have long been described in the psychological
and psychiatric literature, formalized diagnostic criteria
for CG have only been recently proposed and are not
yet part of the formal diagnostic nomenclature, limiting
the development of an evidence base for targeted phar-
macotherapy interventions. To date, randomized con-
trolled research is only available for the efficacy of spe-
cific psychological interventions to treat this condition.
35
Though there have been some open-label and small
studies on pharmacological interventions, well-designed
and powered efficacy studies on the pharmacological
treatment of this condition are still lacking. Results from
several open-label studies suggest that while tricyclic
antidepressants might not be specifically efficacious for
grief symptoms, SSRIs might be of potential use in the
management of this debilitating condition, both as stand-
alone treatments or in conjunction with specific psy-
chotherapies. A large multisite randomized controlled
trial is currently underway testing the differential effi-
cacy of citalopram, citalopram plus CGT, and CGT plus
pill placebo versus pill placebo.
37
Recent advances in our understanding of the neurobiol-
ogy of CG may also help develop innovative treatment
strategies. Complicated grief has been hypothesized to
involve reward-related brain systems that have been sug-
gested to be related to attachment behavior.
38A recent
neuroimaging study found that, while both individuals
with noncomplicated grief and those with CG display
activity in pain-related neural networks in response to
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nucleus accumbens was only found in those with CG.
39
This result is similar to that reported in studies on addic-
tion and indicates that the absence of successful adapta-
tion after a loss may involve persistent “craving” mecha-
nisms. Activity in the nucleus accumbens, which plays a
central role in the reward system, has been shown to be
intimately linked to increased dopaminergic activity.
40
Attempts to pharmacologically treat addiction with
dopaminergic agents have previously been tried. To date,
however, trials of dopaminergic antagonists (ie, antipsy-
chotic agents) in the treatment of substance-related dis-
orders have yielded mixed results with, for example, pos-
itive results of quetiapine on craving in alcohol
dependence
41,42 contrasting with negative results of olan-
zapine and risperidone in cocaine dependence.
43,44
Nonetheless, these preliminary data suggest that phar-
macological manipulation of craving might be possible
and that agents targeting dopaminergic transmission the-
oretically might be of potential use in the treatment of
complicated grief when craving and longing are the core
symptoms. However, to date, there is clearly no current
indication for the use of antipsychotics as a primary treat-
ment for CG, and given their safety profiles they are
unlikely to be a first-line approach in the future.
Finally, recent research also suggests that CG symptoms
may be associated with specific physiological
45 and bio-
logical features
16 that might provide insight into novel
treatment approaches. In particular, Bonanno et al
45
reported that CG symptoms were associated with
decreased heart rate reactivity when talking about the
deceased one, suggested that sympathetic or parasym-
pathetic activity might be involved in the pathophysiol-
ogy of CG and that pharmacological manipulation of
these systems might also be a potentially interesting
treatment approach.
Conclusions
There is some tantalizing early data suggesting that
treatment with an SSRI may improve both the depres-
sive and grief-specific symptoms experienced in compli-
cated grief. Furthermore, antidepressant administration
may make therapeutic interventions more effective.
Further studies on the role of antidepressants are indi-
cated before definitive conclusions may be drawn, as
well as research examining the role of other neuro-
transmitter systems and stress pathways to better eluci-
date the biology and pharmacotherapy of complicated
grief. ❏
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Propuestas farmacológicas para el 
tratamiento del duelo complicado: 
razones principales y una breve 
revisión de la literatura
El duelo complicado (DC) es una causa común y a
menudo subestimada de deterioro profundo que se
experimenta después de la muerte de un ser que-
rido. Aunque la investigación clínica y básica
sugiere que los fármacos pueden ser útiles en el tra-
tamiento del DC, todavía es escasa la investigación
sobre los aspectos farmacológicos de este cuadro.
Tres estudios de diseño abierto y uno randomizado
sobre la depresión asociada con el duelo sugieren
que los antidepresivos tricíclicos pueden ser efecti-
vos, aunque ellos pueden resultar más eficaces para
los síntomas depresivos que para los síntomas espe-
cíficos del duelo. Cuatro estudios de diseño abierto
(con un total de 50 participantes) de inhibidores
selectivos de la recaptura de serotonina (ISRS) han
obtenido resultados, proporcionando una base muy
preliminar sobre la eficacia en el tratamiento del
DC, ya sea empleados en forma exclusiva o en com-
binación con intervenciones psicoterapéuticas. Estos
estudios más recientes han mostrado un efecto en
las escalas de depresión y aquéllas específicas para
duelo. Además las intervenciones terapéuticas para
el DC pueden ser más efectivas cuando se combinan
con la administración de ISRS. Dado que a la fecha
se dispone de pocos estudios farmacológicos, se
requiere de estudios randomizados para evaluar la
potencial eficacia de los fármacos en el tratamiento
del DC.
Traitements pharmacologiquesdu deuil 
compliqué : argumentaire et brève revue 
de la littérature.
Le deuil compliqué (DC) est une cause courante et
souvent méconnue d’incapacité importante après
la perte d’un être aimé. La recherche, qu’elle soit
clinique ou fondamentale, suggère que des traite-
ments pharmacologiques pourraient être utilisés
dans ce contexte mais elle est encore pauvre sur ce
sujet. D’après trois études en ouvert et une étude
randomisée sur la dépression liée au deuil, les anti-
dépresseurs tricycliques pourraient être efficaces
bien qu’ils soient plus actifs sur les symptômes
dépressifs que sur les symptômes spécifiques du DC.
Les résultats très préliminaires de quatre études en
ouvert (nombre total de participants, 50) sur les
inhibiteurs sélectifs de la recapture de la sérotonine
(ISRS) montrent qu’ils pourraient être efficaces dans
le traitement du DC à la fois en traitement unique
et en association à des actions psychothérapeu-
tiques. Ces études plus récentes ont montré un effet
sur les échelles à la fois de la dépression et celles
spécifiques du DC. De plus, les approches théra-
peutiques du DC peuvent voir leur action renforcée
par l’administration simultanée d’ISRS. Compte
tenu du faible nombre d’études pharmacologiques
à ce jour, d’autres études randomisées sont néces-
saires pour évaluer l’efficacité potentielle des
agents pharmacologiques dans le traitement du DC.
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